Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Diabetes Mellitus · Hemophilia A

Takeda

Takeda clinical programs — 1179 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Cambridge, USA HQ
1993 Founded
1,617 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Cambridge, USA
Founded
1993
Employees
1,617
Programs
1179
Drugs
359
Patents
1436
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

Takeda projects

1,179 ClinicalTrials.gov programs sponsored by Takeda.

Takeda has 1,179 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

1,179 programs

Clinical programs

Page 2 of 25

  1. BAX 326 (Recombinant factor IX)

    Takeda

    Hemophilia B

    phase 3 mab completed

    1 trial

  2. BAX326

    Takeda

    Hemophilia B

    phase 3 mab completed

    1 trial

  3. BAX855

    Takeda

    Hemophilia A

    phase 3 mab completed

    1 trial

  4. Brentuximab Vedotin

    Takeda

    Primary Cutaneous Anaplastic Large Cell Lymphoma

    phase 3 small molecule completed

    1 trial

  5. Brentuximab vedotin

    Takeda

    Diffuse Large B-cell-lymphoma

    phase 3 small molecule active

    1 trial

  6. Brigatinib

    Takeda

    ALK+ Advanced NSCLC

    phase 3 small molecule completed

    1 trial

  7. Budesonide oral suspension

    Takeda

    Eosinophilic Esophagitis (EoE)

    phase 3 small molecule terminated

    1 trial

  8. C1 esterase inhibitor [human] (C1INH-nf)

    Takeda

    Hereditary Angioedema

    phase 3 mab completed

    5 trials

  9. C1 esterase inhibitor [human] liquid

    Takeda

    Hereditary Angioedema (HAE)

    phase 3 small molecule completed

    1 trial

  10. C25003

    Takeda

    Advanced Classical Hodgkin Lymphoma

    phase 3 small molecule active

    1 trial

  11. CINRYZE 500

    Takeda

    Hereditary Angioedema (HAE)

    phase 3 mab completed

    1 trial

  12. CINRYZE 500 U

    Takeda

    Hereditary Angioedema (HAE)

    phase 3 small molecule completed

    1 trial

  13. Cabozantinib

    Takeda

    Metastatic Prostate Cancer

    phase 3 small molecule active

    1 trial

  14. Candesartan

    Takeda

    Heart Failure

    phase 3 small molecule completed

    1 trial

  15. Candesartan Cilexetil

    Takeda

    Stroke

    phase 3 small molecule completed

    1 trial

  16. Candesartan and standard chronic heart disease therapy

    Takeda

    Heart Failure

    phase 3 small molecule terminated

    1 trial

  17. Cinryze®

    Takeda

    Acute Antibody-Mediated Rejection (AMR)

    phase 3 mab terminated

    1 trial

  18. Cohort 1: Lubiprostone Capsule, Fasted

    Takeda

    Healthy Volunteers

    phase 3 small molecule completed

    1 trial

  19. Cx601

    Takeda

    Crohn's Disease

    phase 3 other completed

    3 trials

  20. Cyclobenzaprine HCl

    Takeda

    Neck Pain

    phase 3 small molecule completed

    1 trial

  21. Cyproterone acetate

    Takeda

    Adenocarcinoma, Prostate

    phase 3 small molecule completed

    1 trial

  22. DC 06/02

    Takeda

    Adrenal Insufficiency

    phase 3 small molecule completed

    1 trial

  23. DEN-303

    Takeda

    Dengue Fever

    phase 3 mab completed

    1 trial

  24. DX-2930

    Takeda

    Hereditary Angioedema (HAE)

    phase 3 small molecule completed

    3 trials

  25. DX-2930 - 300mg/2wk

    Takeda

    Hereditary Angioedema (HAE)

    phase 3 small molecule completed

    1 trial

  26. Darvadstrocel

    Takeda

    Complex Perianal Fistulas in Adult Participants With Crohn's Disease

    phase 3 mab completed

    1 trial

  27. Delayed and extended release mesalazine

    Takeda

    Colitis, Ulcerative

    phase 3 small molecule completed

    1 trial

  28. Dexlansoprazole

    Takeda

    Heartburn

    phase 3 small molecule completed

    1 trial

  29. Dexlansoprazole

    Takeda

    Erosive Esophagitis

    phase 3 small molecule terminated

    2 trials

  30. Dexlansoprazole

    Takeda

    Gastroesophageal Reflux

    phase 3 small molecule completed

    2 trials

  31. Dexlansoprazole MR

    Takeda

    Esophagitis, Reflux

    phase 3 small molecule completed

    5 trials

  32. Dexlansoprazole MR

    Takeda

    Gastroesophageal Reflux Disease

    phase 3 small molecule completed

    4 trials

  33. Dexlansoprazole MR QD

    Takeda

    Gastroesophageal Reflux

    phase 3 small molecule completed

    1 trial

  34. Doxorubicin

    Takeda

    Hodgkin Lymphoma

    phase 3 small molecule active

    1 trial

  35. Dynepo (Epoetin delta)

    Takeda

    Anemia

    phase 3 small molecule terminated

    1 trial

  36. ERYTHROPOIETIN , Elritercept

    Takeda

    Myelodysplastic neoplasms/syndromes (MDS)

    phase 3 small molecule active

    1 trial

  37. Elritercept

    Takeda

    Myelodysplastic Syndrome

    phase 3 small molecule active

    1 trial

  38. Emicizumab

    Takeda

    Hemophilia A

    phase 3 small molecule active

    1 trial

  39. Epoetin

    Takeda

    Chronic Kidney Disease

    phase 3 small molecule completed

    1 trial

  40. Escitalopram

    Takeda

    Major Depressive Disorder

    phase 3 small molecule terminated

    1 trial

  41. Expanded autologous adipose-derived adult stem cells (eASCs)

    Takeda

    Complex Perianal Fistula

    phase 3 small molecule terminated

    1 trial

  42. Extended-release Guanfacine Hydrochloride

    Takeda

    Attention-deficit/Hyperactivity Disorder

    phase 3 small molecule completed

    3 trials

  43. FEIBA

    Takeda

    Hemophilia A or B With Inhibitors

    phase 3 mab completed

    1 trial

  44. FST-201 (dexamethasone 0.1%) Otic Suspension

    Takeda

    Acute Fungal Otitis Externa

    phase 3 small molecule terminated

    1 trial

  45. FST-201 (dexamethasone 0.1%) Otic Suspension

    Takeda

    Acute Otitis Externa

    phase 3 small molecule terminated

    1 trial

  46. FST201 (dexamethasone 0.1% with povidone-iodine 1%)

    Takeda

    Acute Otitis Externa

    phase 3 small molecule completed

    1 trial

  47. Fasiglifam (TAK-875)

    Takeda

    Glycemic Control

    phase 3 small molecule terminated

    1 trial

  48. Fasiglifam (TAK-875)

    Takeda

    Diabetes Mellitus, Type 2

    phase 3 small molecule terminated

    1 trial

Frequently asked questions

How many clinical projects does Takeda have?

1,179 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.